Adagene to Present at Jefferies Global Healthcare Conference 2025 May 27, 2025 07:30AM
Adagene Inc. (ADAG) updates data from Phase 1b/2 study of Muzastotug May 22, 2025 05:08PM
Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annu May 22, 2025 05:05PM
Adagene Appoints John Maraganore, Ph.D. as Executive Advisor Apr 28, 2025 08:00AM
Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting Apr 23, 2025 10:05AM
View Older Stories

Apr 7, 2025 08:00AM Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum
Mar 24, 2025 08:00AM Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update
Mar 13, 2025 08:00AM Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit
Mar 6, 2025 08:00AM Adagene to Present at Leerink’s Global Healthcare Conference 2025
Feb 27, 2025 08:00AM Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer
Jan 27, 2025 07:01AM Adagene Inc. (ADAG) Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA
Jan 27, 2025 07:00AM Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium
Jan 27, 2025 07:00AM Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium
Jan 21, 2025 05:00PM Adagene Inc. (ADAG) to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA
Jan 21, 2025 05:00PM Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium
Jan 14, 2025 08:00AM Adagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 SAFEbody® ADG126 in Advanced/Metastatic Microsatellite-Stable (MSS) Colorectal Cancer (CRC) on January 25, 2025
Nov 7, 2024 10:01AM Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Mono
Oct 9, 2024 06:00AM Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Sep 16, 2024 03:01AM Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metas
Aug 29, 2024 07:00AM Adagene to Participate in Investor Conferences in September
Jul 25, 2024 04:05PM Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update
Jul 12, 2024 07:00AM Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congre
May 22, 2024 04:45PM Adagene to Present at Investor Conferences in June
Mar 29, 2024 09:00AM Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
Mar 7, 2024 04:01PM Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
Feb 27, 2024 08:00AM Adagene to Present at the Leerink Partners Global Biopharma Conference 2024
Feb 9, 2024 06:01AM Adagene (ADAG) Announces Progress and Expansion of Clinical Collaboration Program for ADG126 in Combination with KEYTRUDA
Feb 9, 2024 06:00AM Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further
Jan 16, 2024 05:02PM Adagene Inc. (ADAG) Presents Interim Results Reinforcing Best-in-Class Profile of ADG126
Jan 16, 2024 05:01PM Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colo
Jan 4, 2024 05:00AM Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium
Nov 3, 2023 12:03PM Adagene Inc. (ADAG) Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody ADG126
Nov 3, 2023 12:00PM Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023
Oct 12, 2023 08:00AM Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Sep 7, 2023 06:00AM Adagene to Present at Investor and Scientific Conferences in September
Aug 31, 2023 07:32AM Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update
Apr 18, 2023 09:19AM Adagene (ADAG) Presents Clinical Data for Anti-CTLA-4 SAFEbody ADG126
Apr 18, 2023 09:17AM Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors
Apr 18, 2023 09:17AM Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors
Mar 28, 2023 04:32PM Adagene (ADAG) Reports FY22, Provides Corporate Update
Mar 28, 2023 04:32PM Adagene (ADAG) Reports FY22, Provides Corporate Update
Mar 28, 2023 04:30PM Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update
Mar 28, 2023 04:30PM Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update
Mar 14, 2023 06:00PM Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April
Mar 14, 2023 06:00PM Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April
Mar 6, 2023 05:55AM Adagene Inc. (ADAG) Appoints Aurélien Marabelle to its Board
Mar 5, 2023 07:39PM Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board
Mar 5, 2023 07:39PM Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board
Jan 27, 2023 06:11AM Adani Group shares slide further as Hindenburg row heats up
Jan 5, 2023 04:01PM Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9
Jan 5, 2023 04:01PM Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9
Dec 16, 2022 06:32AM Adagene Inc. (ADAG) Announces Clinical Trial Collaboration for ADG126
Dec 16, 2022 06:30AM Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche’s Standard-of-Care for First-Line Advanced Liver Cancer
Dec 16, 2022 06:30AM Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche’s Standard-of-Care for First-Line Advanced Liver Cancer
Nov 21, 2022 04:07PM Adagene Inc. (ADAG) Appoints Cuong Do to its Board
View Older Stories